A five year study, sponsored by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health is showing promising results. Currently (at the three year mark of the five year study), a team of nationwide researchers released an interim report of their findings. The clinical trial involves the “transplantation of the individuals’ own hematopoietic (blood cell-producing) stem cells combined with high-dose immunotherapy in 24 people with relapsing-remitting MS. This procedure aims at “rebooting” the immune system to prevent MS immune attacks against the brain and spinal cord. At three years, 78.4% of participants experienced no new disease activity.”
To read the full article, please visit http://www.nationalmssociety.org/About-the-Society/News/Interim-Results-Reported-from-Clinical-Trial-of-St.
Source: National MS Society